Hepatitis C virus NS3-4A serine protease inhibitors: Use of a P2–P1 cyclopropyl alanine combination for improved potency
- 15 October 2005
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (20) , 4515-4519
- https://doi.org/10.1016/j.bmcl.2005.07.009
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as Hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complexBioorganic & Medicinal Chemistry Letters, 2004
- Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymeraseAntiviral Research, 2003
- Hepatitis C Virus Serine Protease Inhibitors: Current Progress and Future ChallengesCurrent Medicinal Chemistry, 2001
- Emerging therapies for hepatitis C virus infectionEmerging Drugs, 2001
- Replication of hepatitis C virusMicrobiology, 2000
- Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In VivoJournal of Virology, 2000
- The Scientific Challenge of Hepatitis CScience, 1999
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- Hepatitis C virus NS3/4A proteaseAntiviral Research, 1998
- Hepatitis C: progress and problemsClinical Microbiology Reviews, 1994